INTRODUCTION {#s1}
============

Anoikis is a form of programmed cell death that occurs in anchorage-dependent cells when they detach from the surrounding extracellular matrix \[[@R1]--[@R3]\]. Anoikis acts as an important defense for the organism by preventing detached cells' re-adhesion to new matrices in incorrect locations and their dysplastic growth \[[@R4]\]. Failure to execute the anoikis program and resistance to anoikis evolve as a hallmark of metastatic cancers which enables cancer cells to disseminate to distant organs through systemic circulation \[[@R5]--[@R7]\].

Tropomyosin-related receptor Kinase B (TrkB) is a tyrosine kinase receptor for brain-derived neutrophic factor (BDNF), which triggers several intracellular signals \[[@R8]--[@R10]\]. TrkB was originally defined as a specific suppressor of caspase-associated anoikis of non-malignant epithelial cells. High expression of TrkB promoted tumorigenesis and metastasis. The vast bulk of the evidence from studies on solid tumor cells of liver, lung, breast and ovary indicated that anoikis suppression induced by over-expressed TrkB best owed enhanced metastatic capacity on various tumor cells \[[@R11]--[@R14]\]. Therefore, TrkB is expected to be a potential drug target \[[@R15], [@R16]\]. the correlation between the expression of TrkB and patient survival remains inconclusive. Therefore, it is necessary to analyze the data of TrkB systematically in human solid tumors to draw a reasonable conclusion about its prognostic significance.

In this study, we conducted a meta-analysis to investigate the significance of over-expressed TrkB in the prediction of prognosis of corresponding patients. The results showed that increased TrkB expression in patients with solid tumors related to poor prognosis and served as a potential prediction of poor clinicopathological prognosis factor.

RESULTS {#s2}
=======

Study search information {#s2_1}
------------------------

The initial search identified 315 publications, of which, 18 studies were of acceptable relevance. However, four of these studies were excluded because the survival curve was based on NTRK2 expression, and three were excluded because of the absence of information about clinicopathological characteristics. Ultimately, 11 studies met the eligibility criteria and were included in the current meta-analysis (Figure [1](#F1){ref-type="fig"}).

![Flow diagram of the selection of eligible studies](oncotarget-08-99394-g001){#F1}

Description of the studies {#s2_2}
--------------------------

The characteristics of the 11 identified studies were shown in Table [1](#T1){ref-type="table"}. In total, 1516 patients from three regions (China, Greece and Japan) with 8 distinct cancers (gastric cancers \[[@R17]--[@R19]\], colorectal cancers \[[@R20], [@R21]\], nasopharyngeal carcinoma \[[@R22]\], non-small cell lung cancers \[[@R23]\], ovarian cancers \[[@R24]\], oral squamous cell carcinoma \[[@R25]\], hepaticellular carcinoma \[[@R26]\], sinonasal squamous cell carcinoma \[[@R27]\]) were included in these studies.

###### Main characteristics of studies exploring the relationship between TrkB expression and tumor prognosis

  Author                  Year   Region   Cancer Type   Stage / Grade   No. of Patients   Age Median (Range)   Follow-up Time Median (range)   Detection Method   Staining position            Cut-off        Outcomes   NOS Score
  ----------------------- ------ -------- ------------- --------------- ----------------- -------------------- ------------------------------- ------------------ ---------------------------- -------------- ---------- -----------
  Tanaka K \[[@R16]\]     2014   Japan    GC            pT1-pT4         320               68 y (18--90)        25.9 m (1.4--124.5)             IHC                Both nucleus and cytoplasm   \> 10%         OS         8
  Fan M \[[@R19]\]        2014   China    CRC           I--IV           191               NR                   NR                              IHC                No specific description      \> 10%         OS         8
  Li SS \[[@R21]\]        2013   China    NPC           I--IV           108               56 y (19--86)        60 m                            IHC                Cytoplasm                    \> 10%         DFS, OS    7
  Okugawa Y \[[@R17]\]    2013   Japan    GC            I--IV           150               NR                   NR                              IHC                Both nucleus and cytoplasm   \> 10%         OS         8
  Okamura K \[[@R22]\]    2012   Japan    NSCLC         I--IV           102               66.3 ± 10.19 y       1470 d                          IHC                Membrane and cytoplasm       \> 10%         DFS, OS    7
  Sasahira T \[[@R24]\]   2013   Japan    OSCC          I--IV           102               68.7 y (48--79)      NR                              IHC                Cytoplasm                    \> 10%         DFS        7
  Au CW \[[@R23]\]        2009   China    OC            I--IV           94                20--83               NR                              IHC                Membrane and cytoplasm       \> 10%         DFS, OS    6
  Zhang Y \[[@R18]\]      2008   Japan    GC            pT1-pT4         161               63 y (34--100)       NR                              IHC                Cytoplasm                    \> 10%         DFS, OS    7
  Dawson H \[[@R20]\]     2015   Greece   CRC           pT1-pT4         211               70.5 y (35--93)      NR                              IHC                Membrane and cytoplasm       Membrane (+)   OS         8
  Lam CT \[[@R25]\]       2011   China    HCC           I--IV           50                55 y (30--82)        NR                              IHC                Membrane and cytoplasm       \> 10%         OS         6
  Li L \[[@R26]\]         2016   China    SSCC          I--IV           27                55 y (34--74)        NR                              IHC                Membrane and cytoplasm       \> 10%         DFS, OS    5

GC: Gastric Cancers; CRC: Colorectal Cancers; NPC: Nasopharyngeal Carcinoma; NSCLC: Non-Small Cell Lung Cancers; OC: Ovarian Cancers; OSCC: Oral Squamous Cell Carcinoma; HCC: Hepatocellular Carcinoma; SSCC: Sinonasal Squamous Cell Carcinoma; NR: Not Reported; OS: Overall Survival; DFS: Disease-Free Survival.

Correlations of TrkB expression and OS {#s2_3}
--------------------------------------

The pooled hazard ratio (HR) revealed that over-expressed TrkB was significantly associated with poor overall survival (OS) for cancer victims in multivariate analysis (HR: 1.76, 95% CI: 1.48--2.10; Figure [2](#F2){ref-type="fig"}). However, no significant heterogeneity (*I*^2^ = 31.6%, *P* = 0.147) was observed when using a fixed-effects model to analyze the pooled HR of the OSs.

![Forest plot describing the association between over-expressed TrkB and OS](oncotarget-08-99394-g002){#F2}

Correlations of TrkB expression and DFS {#s2_4}
---------------------------------------

A significant correlation between over-expressed TrkB and disease-free survival (DFS) was also observed in the patients with solid tumors in multivariate analysis (HR: 2.20, 95% CI: 1.63--2.96; Figure [3](#F3){ref-type="fig"}) in the fixed-effects model without significant heterogeneity (*I*^2^ = 0.0%, *P* = 0.419).

![Forest plot describing the association between over-expressed TrkB and DFS](oncotarget-08-99394-g003){#F3}

Correlations of TrkB expression and clinicopathological parameters {#s2_5}
------------------------------------------------------------------

The clinical and pathological parameters collected from the eligible studies were presented in Table [2](#T2){ref-type="table"}. Meanwhile, pooled results of the correlations were identified between over-expressed TrkB and clinicopathological features of patients with solid tumors. No significant correlation of over-expressed TrkB with gender and tumor differentiation were observed. However, the expression of TrkB was positively associated with large tumor size (OR: 1.96, 95% CI: 1.47--2.61), lymph node metastasis (OR: 1.93, 95% CI: 1.50--2.48), distant metastasis (OR: 2.76, 95% CI: 1.78--4.26) and a higher clinical stage (OR: 1.78, 95% CI: 1.16--2.72) in the fixed-effects model without significant heterogeneities (see Table [3](#T3){ref-type="table"}).

###### Summarized data of clinical and pathological parameters from the eligible studies

  First author               Gender   Tumor differentiation   Tumor size   Lymph node metastasis   Distant metastasis   Clinical stage                                                                                              
  ----------------------- -- -------- ----------------------- ------------ ----------------------- -------------------- ---------------- ---- ----- ---- ----- ---- ----- ---- ----- ---- ----- ---- ---- ---- ----- ---- ---- ---- -----
  Tanaka K \[[@R16]\]        50       181                     17           72                      24                   143              43   110   47   129   20   124   43   119   24   134   6    11   61   242   37   94   30   159
  Fan M \[[@R19]\]           49       52                      56           34                      66                   57               39   29    NA   NA    NA   NA    52   21    53   65    18   6    87   80    40   32   65   54
  Li SS \[[@R21]\]           31       56                      12           9                       39                   61               4    4     24   21    19   44    38   43    5    22    7    5    36   60    42   52   1    13
  Okugawa Y \[[@R17]\]       54       65                      10           21                      25                   50               39   36    46   52    18   34    50   55    14   31    6    6    58   80    47   55   17   31
  Okamura K \[[@R22]\]       54       18                      23           7                       56                   15               13   9     9    4     68   21    26   6     51   19    NA   NA   NA   NA    16   4    61   21
  Sasahira T \[[@R24]\]      21       47                      11           23                      11                   27               21   43    19   32    13   38    17   30    15   40    NA   NA   NA   NA    23   42   9    28
  Zhang Y \[[@R18]\]         43       67                      21           30                      20                   51               44   46    27   22    37   75    27   34    37   63    14   3    50   94    NA   NA   NA   NA
  Dawson H \[[@R20]\]        27       41                      26           46                      48                   74               4    13    44   71    8    16    31   48    21   39    11   8    42   78    NA   NA   NA   NA
  Li L \[[@R26]\]            13       7                       5            2                       15                   3                3    6     14   4     4    5     6    1     12   8     NA   NA   NA   NA    16   4    2    5

###### Meta-analysis results of the associations of increased TrkB expression with clinicopathological parameters

  Clinicopathological parameter       Ref                                                          Overall OR (95% CI)    *P*-value   Heterogeneity test (*Q*, *I*^2^, *P*-value)
  ----------------------------------- ------------------------------------------------------------ ---------------------- ----------- ---------------------------------------------
  Gender (male vs female)             \[[@R16]--[@R22], [@R24], [@R26]\]                           0.907 (0.703--1.169)   0.451       8.52, 6.1%, 0.384
  Differentiation (poor VS well)      \[[@R16]--[@R22], [@R24], [@R26]\]                           0.867 (0.524--1.435)   0.451       25.11, 68.1%, 0.3677
  Tumor size (T3--4 vs T1--2)         \[[@R16]--[@R18], [@R20]--[@R22], [@R24], [@R26]\]           1.960 (1.473--2.608)   0.000       5.83, 0.0%, 0.559
  Lymph node metastasis (yes vs no)   \[[@R16]--[@R22], [@R24], [@R26]\]                           1.927 (1.499--2.477)   0.000       7.51, 0.0%, 0.483
  Distant metastasis (yes vs no)      \[[@R16]--[@R21]\]                                           2.755 (1.781--4.260)   0.000       4.70, 0.0%, 0.453
  Clinical stage (III-IV vs I-II)     \[[@R16]--[@R17], [@R19], [@R21]--[@R22], [@R24], [@R26]\]   1.775 (1.159--2.716)   0.008       9.52, 37.0%, 0.146

Publication bias {#s2_6}
----------------

We constructed funnel plots and performed Begg's test to assess publication bias. As a result, the shape of the funnel plot for the OS, DFS and clinicopathological parameters seemed symmetrical in the multivariate analysis method (Figure [4](#F4){ref-type="fig"}, Figure [5](#F5){ref-type="fig"} and [Supplementary Figure 1](#SD1){ref-type="supplementary-material"}).

![Funnel plot for the assessment of potential publication bias regarding OS in the meta-analysis](oncotarget-08-99394-g004){#F4}

![Funnel plot for the assessment of potential publication bias regarding DFS in the meta-analysis](oncotarget-08-99394-g005){#F5}

DISCUSSION {#s3}
==========

TrkB is a tyrosine kinase receptor for brain-derived neutrophic factor (BDNF), which triggers several intracellular signals. TrkB is over-expressed in various human malignancies and growing evidence demonstrated its association with tumour cell proliferation, invasion and metastasis \[[@R28]--[@R31]\]. TrkB is also an anoikis resistance related gene, whose over-expression may enhance a resistance of detachment-induced apoptosis. Consequently, knockdown of TrkB provided inhibition of growth or invasion and decrease of apoptosis in oral squamous cell carcinoma (OSCC) and endometrial carcinoma cells \[[@R25], [@R32]\]. However, thus far, no meta-analyses have been performed to evaluate the prognostic value of TrkB in cancer victims. This meta-analysis systematically estimates the association between TrkB expression and prognostic value of solid tumors.

In this meta-analysis, we evaluated survival data from 1516 solid tumor patients from 11 eligible studies, which met the inclusion criteria, were organized according to OS and DFS. For all studies, TrkB expression was detected by IHC. By meta-analysis of the 11 studies, we identified the pool HRs which indicated that TrkB was a factor in poor prognosis in various cancers. Because there is no significant heterogeneity among our included studies, so we did not perform further subgroup analyses. Additionally, no publication bias was observed. These results indicated over-expressed TrkB was positive related to poor OS and DFS in solid tumor patients. In addition, pooled results of the correlations were identified between over-expressed TrkB and clinicopathological features of patients with solid tumors. The results showed the expression of TrkB was positively associated with large tumor size, lymph node metastasis, distant metastasis and a higher clinical stage. We can explain this result by TrkB's ability to enhance anoikis resistance, promote tumour cell proliferation, invasion and metastasis. Because of its involvement in these processes, TrkB is likely to be causally involved in tumor progression and, consequently, increased levels of TrkB would be expected to indicate a poor prognosis.

This meta-analysis was properly conducted, however, further analysis with several limitations would be considered in the future. first, need more trials to analysis; second, some of the survival data were extracted from Kaplan-Meier curves and might be less reliable than a direct analysis of variance; third, we need to search more non-English publications. In addition, the possible existence of unpublished studies could also result in potential publication bias. In general, concerning these limitations mentioned above, we must interpret these results with adequate caution.

In conclusion, our meta-analysis indicated that over-expressed TrkB was positive related to poor OS and DFS in solid tumor patients. Over-expressed TrkB could be served as a potential marker for poor clinicopathological prognostic factors in patients with various solid tumors. However, additional studies related to specific tumor types are necessary to illuminate the clinical utility of increased TrkB in solid tumors.

MATERIALS AND METHODS {#s4}
=====================

Literature search strategy {#s4_1}
--------------------------

This systematic review and meta-analysis is reported in accordance with the Preferred Reporting Items for Systematic Review and Meta-Analysis (PRISMA) Statement. The literatures relevant to TrkB expression and survival in solid tumors were searched in the PubMed, Embase and Web of Science databases through March 31, 2017. The search terms included the following key words in various combinations: TrkB, NTRK2, prognosis, prognostic, survival, and overall survival. The hits were limited to human studies and those published in English. The references list of review and bibliographies were further sifted to identify additional potentially relevant studies to avoid omission due to the electronic search approach.

Study inclusion and exclusion criteria {#s4_2}
--------------------------------------

The collected studies included in this meta-analysis had to meet the following criteria: (1) a pathological diagnosis of cancer was made; (2) TrkB expression in patients with any type of tumor was measured via immunohistochemistry; (3) associations of TrkB expression with OS, DFS or clinicopathological features were described; (4) HRs and 95% confidence intervals (CIs) were reported or could be calculated (based on the information in the paper); and (5) when the same author reported repeated results from the same population, the most complete report was included. The exclusion criteria for this meta-analysis were as follows: (1) unpublished papers; (2) laboratory articles, reviews and letters; (3) non-English language articles; (4) overlapping articles or ones with duplicate data; (5) articles with only animal experiments; (6) studies without information about survival curves; and (7) TrkB expression in patients with any type of tumor was analyzed only using RT-PCR method.

Data extraction and quality assessment {#s4_3}
--------------------------------------

All data were extracted independently by two investigators (Chunze Zhang and Dan Gao). For each eligible study, the following characteristics were extracted: first author's name, publication year, region, type of cancer, number of patients, patients' ages, follow-up times, detection methods, staining position, cut-off values, survival data (including OS and DFS) and clinicopathological parameters, such as tumor differentiation, tumor size, lymph node metastasis and TNM stage. For studies that presented only Kaplan-Meier curves was used to extract the survival data. The Newcastle-Ottawa-Scale (NOS) was adopted to assess the study quality of each individual study. The NOS score ranged from 0 to 9, and studies with NOS score ≥ 7 were defined as high-quality studies.

Statistical analysis {#s4_4}
--------------------

This meta-analysis was performed using Stata 12.0 (Stata Corporation, College Station, TX, USA) software. Pooled estimates of HRs and their 95% CIs were used to estimate the association between TrkB expression and patients' survival. The chisquared test (Cochrane' s *Q* test) and I-squared statistical test were used to analyze the heterogeneity between studies. When the result of a *Q*-test (*I*^2^ \> 50% or *P* \< 0.05) indicated heterogeneity, the random-effects model was used for the meta-analysis. Otherwise, a fixed-effects model was used. HR with its value over 1.0 indicated poor prognosis patients with increased TrkB expression. Funnel plots were used to graphically represent the publication bias. Begg's (rank correlation) test was adopted to confirm the publication bias.

SUPPLEMENTARY MATERIALS FIGURE {#s5}
==============================
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